Drugs / Hematopoietic Allogeneic Stem Cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02427178 | Mar 2015 → Jun 2022 | mitochondrial neurogastrointestinal encephalomyopathy | Michio Hirano, MD | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hematopoietic Allogeneic Stem Cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02427178 ↗ |
| Modality | Cell therapy | “Hematopoietic Allogeneic Stem Cells” NCT02427178 ↗ |
| Route | Intravenous | “subsequent IV transfer of stem cells from the donor.” NCT02427178 ↗ |